Interim Results of a Phase I/II Trial of Intermediate-Dose Post-Transplantation Cyclophosphamide after Reduced Intensity Conditioned HLA-Mismatched Bone Marrow Transplantation for Older or Unfit Patients

High-dose post-transplantation cyclophosphamide (PTCy) is standard of care graft-versus-host disease (GVHD) prophylaxis for HLA-mismatched related (HLA-haploidentical, haplo) and HLA-mismatched unrelated (MMUD) donor hematopoietic cell transplantation (HCT). However, the optimal dosing of PTCy has not been defined. Our studies in murine HCT models support that intermediate-dose PTCy may provide superior protection against acute GVHD (aGVHD). A phase I/II study at the National Institutes of Health (NIH) of 25 mg/kg/day PTCy on days +3/+4 after haplo HCT with myeloablative conditioning (MAC) effectively prevented aGVHD, provided faster engraftment, and reduced infection.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Shannon R. McCurdy, Mustafa A. Hyder, Ruby Sabina, Ashley DeVries, Kirstin Chalupa, Natasha Berryman, Jessica Bernhardt, Alison Christina Cusmano, Amy Chai, Rebecca Schwartz, Dimana Dimitrova, Kamil Rechache, Christi McKeown, Anita Stokes, Jennifer Sponau Tags: 3 Source Type: research